RAS/RAF/MEK/ERK(MAPK)信号通路抑制剂在卵巢癌中的潜力:系统综述与Meta分析
该系统综述与Meta分析检索了PubMed、Embase、Cochrane图书馆和clinicaltrials.gov,纳入9项研究共319例卵巢癌患者,评估MAPK通路抑制剂单药或联合治疗的疗效与安全性。合并临床获益率(CBR)为63%(95%CI 39-84%,I²=92%),低级别浆液性卵巢癌(LGSOC)亚组CBR为87%(95%CI 81-92%,I²=0%)、客观缓解率(ORR)为27%(95%CI 10-48%,I²=77%)。作者认为MEK抑制剂是最有前景的单药,BRAFv600突变者可考虑双靶联合。
要点
- MAPK抑制剂在卵巢癌的合并CBR为63%(95%CI 39-84%,I²=92%),异质性高。
- LGSOC亚组CBR为87%(95%CI 81-92%,I²=0%),ORR为27%(95%CI 10-48%,I²=77%)。
- BRAFv600突变LGSOC联合Raf和MEK抑制剂CBR 100%、ORR 83%(n=6)。
核心结论
- MEK抑制剂是(低级别浆液性)卵巢癌最有前景的单药。
- 作者认为BRAFv600突变或经治选择有限的无突变卵巢癌患者可考虑双MAPK通路抑制,因有更高疗效和可耐受毒性谱的迹象。
研究设计与样本
- 系统综述与Meta分析,检索PubMed、Embase via Ovid、Cochrane图书馆和clinicaltrials.gov。
- 纳入9项评估MAPK通路抑制剂单药治疗卵巢癌患者疗效的研究,共319例卵巢癌患者。
- 采用随机效应模型进行Meta分析。
主要发现
- 合并CBR为63%(95%CI 39-84%,I²=92%)。
- BRAFv600突变LGSOC联合Raf和MEK抑制剂(n=6)CBR为100%、ORR为83%。
- LGSOC亚组合并CBR为87%(95%CI 81-92%,I²=0%),ORR为27%(95%CI 10-48%,I²=77%)。
- 167例患者中报告123例次3级或以上不良事件。
关键数值与推荐
- CBR定义为疾病稳定(SD)、完全缓解(CR)和部分缓解(PR)患者比例。
- ORR包括PR和CR。
- 次要结局包括ORR和3、4级不良事件。
临床怎么用
- 作者认为MEK抑制剂是(低级别浆液性)卵巢癌最有前景的单药。
- 作者认为BRAFv600突变或经治选择有限的无突变卵巢癌患者可考虑双MAPK通路抑制。
局限性
- 合并CBR异质性I²=92%。
- LGSOC亚组ORR异质性I²=77%。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The RAS/RAF/MEK/ERK (MAPK) pathway plays a role in ovarian carcinogenesis. Low-grade serous ovarian carcinoma (LGSOC) frequently harbors activating MAPK mutations. MAPK inhibitors have been used in small subsets of ovarian carcinoma (OC) patients to control tumor growth. Therefore, we performed a meta-analysis to evaluate the effectiveness of MAPK inhibitors in OC patients. We aimed to determine the clinical benefit rate (CBR), the subgroup of MAPK inhibitors with the best CBR and overall response rate (ORR), and the most common adverse events. METHODS: We conducted a search in PubMed, Embase via Ovid, the Cochrane library and clinicaltrials.gov on studies evaluating the efficacy of single MAPK pathway inhibition with MAPK pathway inhibitors in OC patients. Our primary outcome included the CBR, defined by the proportion of patients with stable disease (SD), complete (CR) and partial response (PR). Secondary outcomes included the ORR (including PR and CR) and grade 3 and 4 adverse events. Meta-analysis was performed using a random-effects model. RESULTS: We included nine studies with a total of 319 OC patients, for which we determined a pooled CBR of 63% (95%-CI 39-84%, I2 = 92%). Combined treatment with Raf- and MEK inhibitors in in BRAFv600 mutated LGSOC (n = 6) had the greatest efficacy with a CBR of 100% and ORR of 83%. MEK inhibitors had the best efficacy as a single agent. Subgroup analysis by tumor histology demonstrated a significantly higher CBR and ORR in patients with LGSOC, with a pooled CBR and ORR of 87% (95%-CI 81-92%, I2 = 0%) and 27% (95%-CI 10-48%, I2 = 77%) respectively. Adverse events of grade 3 or higher were reported frequently: 123 in 167 patients. CONCLUSIONS: MEK inhibitors are the most promising single agents in (LGS)OC. However, dual MAPK pathway inhibition should be considered in patients with a BRAFv600 mutation, or non-mutated OC with depleted treatment options due indications of higher efficacy and tolerable toxicity profiles.
引用
- Hendrikse CSE, Theelen PMM, van der Ploeg P, et al. The potential of RAS/RAF/MEK/ERK (MAPK) signaling pathway inhibitors in ovarian cancer: A systematic review and meta-analysis. Gynecol Oncol. 2023. PMID: 36841040. doi:10.1016/j.ygyno.2023.01.038
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。